Background: The aim of the paper is to investigate the outcomes of patients younger than 55 years in Victoria, Australia undergoing radical prostatectomy (RP) for prostate cancer. Materials and methods: Data on all men undergoing RP in Victoria between January 1, 2004 and December 31, 2014 were obtained from the Victorian Cancer Registry. Tumor characteristics including Gleason grade, stage of disease (based on final pathology specimen), and cause of death were also obtained. Statistical analysis was performed using Chi-square test, Cox proportional hazards method, and Kaplan-Meier analysis. Results: A total of 14,686 men underwent RP during the defined period. Of these men 109 were aged 35–44 years and 1,998 were aged 45–54 years. Men aged...
Objective. We aimed to evaluate the presenting features and treatment outcome of prostate cancer in ...
In the early 20th century, cancer of the prostate was considered a rare and deadly disease with litt...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...
BACKGROUND: To investigate the outcomes of patients older than 75 years of age in Victoria undergoin...
OBJECTIVE: It is controversial whether age is associated with higher grade and worse outcome. Some s...
Prostate cancer (CaP) in younger men (age ≤50 years) appears to present differently compared with ol...
Objective: It is controversial whether age is associated with higher grade and worse out-come. Some ...
Contains fulltext : 203364.pdf (publisher's version ) (Closed access)OBJECTIVES: T...
Aim. The aim of this study was to describe PCa characteristics and long-term outcomes in young men a...
Objective: To assess the clinicopathological features and overall survival between two groups of Chi...
OBJECTIVES:To investigate perioperative, oncologic, and functional outcomes of robot-assisted radica...
It is not clear to what extent the age of diagnosis and the attained age impact on cancer mortality ...
Objective: To assess the influence of age in pathological findings and clinical evolution of prostat...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
Background: Recently, younger prostate cancer (PCa) patients have been reported to harbour more favo...
Objective. We aimed to evaluate the presenting features and treatment outcome of prostate cancer in ...
In the early 20th century, cancer of the prostate was considered a rare and deadly disease with litt...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...
BACKGROUND: To investigate the outcomes of patients older than 75 years of age in Victoria undergoin...
OBJECTIVE: It is controversial whether age is associated with higher grade and worse outcome. Some s...
Prostate cancer (CaP) in younger men (age ≤50 years) appears to present differently compared with ol...
Objective: It is controversial whether age is associated with higher grade and worse out-come. Some ...
Contains fulltext : 203364.pdf (publisher's version ) (Closed access)OBJECTIVES: T...
Aim. The aim of this study was to describe PCa characteristics and long-term outcomes in young men a...
Objective: To assess the clinicopathological features and overall survival between two groups of Chi...
OBJECTIVES:To investigate perioperative, oncologic, and functional outcomes of robot-assisted radica...
It is not clear to what extent the age of diagnosis and the attained age impact on cancer mortality ...
Objective: To assess the influence of age in pathological findings and clinical evolution of prostat...
Context: The appropriate therapy for men with clinically localized prostate cancer is uncertain. A r...
Background: Recently, younger prostate cancer (PCa) patients have been reported to harbour more favo...
Objective. We aimed to evaluate the presenting features and treatment outcome of prostate cancer in ...
In the early 20th century, cancer of the prostate was considered a rare and deadly disease with litt...
Background: Many elderly men with high-risk nonmetastatic prostate cancer (HRnMPCa) do not receive r...